Autolus Therapeutics (AUTL) EBT Margin (2017 - 2025)
Autolus Therapeutics (AUTL) posted quarterly EBT Margin of 376.78% for Q4 2025, up 8977495.0% year-on-year from N/an in Q4 2024, and down 1.61% on a QoQ basis from 370.79% in Q3 2025.
Autolus Therapeutics (AUTL) EBT Margin (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported EBT Margin for 9 consecutive years, with 376.78% the latest figure, recorded in Q4 2025.
- Quarterly EBT Margin rose 8977495.0% year-over-year to 376.78% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 378.78% (up 178466.0% YoY) and the FY2025 annual result came in at 378.78%, up 178657.0% from the prior year.
- EBT Margin retreated to 376.78% in Q4 2025 per AUTL's latest filing, from 370.79% in the prior quarter.
- Over the last five years, EBT Margin for AUTL reached as high as 203.03% in Q4 2022 and fell as low as 90151.72% in Q4 2024.
- A 5-year average of 11781.28% and a median of 2214.29% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 949254 bps — and 2025, when it jumped 8977495 bps.
- Year by year, EBT Margin stood at 16684.75% in 2021, then surged by 99 bps to 203.03% in 2022, then plunged by 5465 bps to 11298.03% in 2023, then tumbled by 698 bps to 90151.72% in 2024, then soared by 100 bps to 376.78% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 376.78%, 370.79%, and 227.12% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -376.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -376.78% |
| Sep 30, 2025 | -370.79% |
| Jun 30, 2025 | -227.12% |
| Mar 31, 2025 | -756.36% |
| Dec 31, 2024 | -90,151.72% |
| Mar 31, 2024 | -521.76% |
| Sep 30, 2023 | -11,298.03% |
| Mar 31, 2023 | -3,082.43% |
| Dec 31, 2022 | -203.03% |
| Sep 30, 2022 | -1,805.49% |
| Mar 31, 2022 | -22,342.17% |
| Sep 30, 2021 | -16,684.75% |
| Jun 30, 2021 | -2,623.09% |
| Mar 31, 2021 | -14,494.42% |
| Dec 31, 2020 | -11,990.59% |
| Sep 30, 2020 | -10,315.07% |
| Jun 30, 2020 | -13,333.11% |
| Mar 31, 2020 | -9,931.66% |
| Jun 30, 2019 | -2,708.56% |
| Mar 31, 2019 | -1,558.04% |